000058437 001__ 58437
000058437 005__ 20200221144259.0
000058437 0247_ $$2doi$$a10.1007/s12325-016-0461-z
000058437 0248_ $$2sideral$$a97413
000058437 037__ $$aART-2016-97413
000058437 041__ $$aeng
000058437 100__ $$aAndrés-Guerrero, V.
000058437 245__ $$aCurrent perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma
000058437 260__ $$c2016
000058437 5060_ $$aAccess copy available to the general public$$fUnrestricted
000058437 5203_ $$aThe approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.
000058437 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/MAT2013-43127R
000058437 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000058437 590__ $$a2.709$$b2016
000058437 591__ $$aPHARMACOLOGY & PHARMACY$$b114 / 256 = 0.445$$c2016$$dQ2$$eT2
000058437 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b58 / 128 = 0.453$$c2016$$dQ2$$eT2
000058437 592__ $$a0.973$$b2016
000058437 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000058437 593__ $$aPharmacology (medical)$$c2016$$dQ2
000058437 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000058437 700__ $$aPerucho-González, L.
000058437 700__ $$aGarcía-Feijoo, J.
000058437 700__ $$aMorales-Fernández, L.
000058437 700__ $$aSaenz-Francés, F.
000058437 700__ $$aHerrero-Vanrell, R.
000058437 700__ $$0(orcid)0000-0003-2389-8282$$aPablo Júlvez, L.$$uUniversidad de Zaragoza
000058437 700__ $$0(orcid)0000-0002-1402-3129$$aPolo Llorens, V.$$uUniversidad de Zaragoza
000058437 700__ $$aMartínez-de-la-Casa, J.M.
000058437 700__ $$aKonstas, A.G P.
000058437 7102_ $$11004$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Oftalmología
000058437 773__ $$g(2016), 1-18$$pAdv. ther.$$tADVANCES IN THERAPY$$x0741-238X
000058437 8564_ $$s704769$$uhttps://zaguan.unizar.es/record/58437/files/texto_completo.pdf$$yVersión publicada
000058437 8564_ $$s81950$$uhttps://zaguan.unizar.es/record/58437/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000058437 909CO $$ooai:zaguan.unizar.es:58437$$particulos$$pdriver
000058437 951__ $$a2020-02-21-13:31:44
000058437 980__ $$aARTICLE